Daw-Tsun is a co-founder and Chief Scientific Officer of Elixiron Immunotherapeutics, along with sitting on the board of director. He is an accomplished drug hunter with two decades of R&D leadership and experiences in discovering biologics, small molecules and natural products for treatments of immunological disorders. Previously, he served as Director of Preclinical Pharmacology, Innovative Traditional Chinese Medicine, at GlaxoSmithKline, Shanghai. There, he was responsible for the development of botanical drugs based on traditional Chinese medicines, including one program is currently in Ph2 trial in China for eczema treatment. Prior to joining GSK, Daw-Tsun served in positions of increasing responsibility at Department of Immunology and Inflammation of Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut including Senior Scientist, Principal Scientist and Senior Principal Scientist from 1997 to 2013. There, he led multiple project teams for the discovery and advancement of several drug candidates into clinical development, including small molecule cannabinoid CB2 receptor modulators, bi-specific antibodies using DART technology and monoclonal anti-IL-23 antibody that is currently in Ph3 clinical trials. Daw-Tsun received his Ph.D. in Cell Biology from the University of Pennsylvania and completed post-doctoral training at The Wistar Institute, Philadelphia.